Shares of China's CanSino Biologics rise as much as 15% on W...
Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon.
Cansino and Aerogen are teaming up to develop and market an inhaled version of Cansino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable .
Cansino Biotech rose during the day, once rising more than 15%. It previously announced a partnership with Aerogen to develop the world's first inhaled COVID-19 vaccine.
$CANSINOBIO (06185.HK)$ $CanSino Biologics Inc. (688185.SH)$
Cansino and Aerogen are teaming up to develop and market an inhaled version of Cansino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable .
Cansino Biotech rose during the day, once rising more than 15%. It previously announced a partnership with Aerogen to develop the world's first inhaled COVID-19 vaccine.
$CANSINOBIO (06185.HK)$ $CanSino Biologics Inc. (688185.SH)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Twitter@Sino_Market | Realtime Chinese market info provider.
9467Followers
4Following
8950Visitors
Follow